Scholar Rock Holding Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRRK research report →
Range $58 – $84
Price Chart
About the company
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies.
- CEO
- David L. Hallal
- IPO
- 2018
- Employees
- 289
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on SRRK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.87B
- P/E
- -14.71
- Fwd P/E
- 277.68
- PEG
- 28.22
- P/S
- 10141.31
- P/B
- 37.18
- EV/EBITDA
- -14.10
- Div Yield
- 0.00%
- Gross Margin
- -8235.96%
- Op Margin
- -71732.28%
- Net Margin
- -72563.16%
- ROE
- -175.27%
- ROIC
- -110.01%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-208,440,000-10661.0%
- Op Income
- $-384,645,000
- Net Income
- $-377,939,000-53.5%
- EPS
- $-3.29-33.2%
- OCF Growth
- -49.3%
- FCF Growth
- -49.5%
- 52W High
- $61.76
- 52W Low
- $38.02
- 50D MA
- $45.43
- 200D MA
- $48.25
- Beta
- 0.62
- RSI (14)
- 56
- Avg Volume
- 1.85M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Scholar Rock reported an encouraging early U.S. launch for ISEMBYLD, with strong patient demand, early payer wins, and a strengthened balance sheet from a planned $205 million voucher sale.· November 10, 2026
- FDA approved ISEMBYLD in mid-September and the company said it began the U.S. launch immediately.
- Third-quarter revenue was $0.6 million, reflecting initial inventory shipped to the specialty network.
- Cash, cash equivalents and marketable securities were $413.6 million at quarter-end, before the expected $205 million priority review voucher sale.
- Management said early demand is broad-based, with more than 1/3 of the top 140 SMA centers enrolling patients and payer discussions reaching more than 90% of covered lives.
- Regulatory progress continued ex-U.S., with the apitegromab MAA resubmitted in Europe and the Japan filing submitted 2 months ahead of guidance.
Third-quarter revenue was $0.6 million, reflecting initial ISEMBYLD inventory shipments to the specialty network. Total operating expenses were $106.6 million, including $17.9 million of noncash stock-based compensation; excluding stock-based comp, operating expenses were $88.7 million. The company ended the quarter with $413.6 million in cash, cash equivalents and marketable securities. Management said the priority review voucher sale for $205 million will further strengthen the balance sheet, and approval of ISEMBYLD also gives access to an additional $150 million under the existing debt facility. No formal quarterly or full-year revenue guidance was provided; management said the majority of patients enrolled through October are expected to start infusions in 2027, with revenues expected to grow steadily over time.
David Hallal framed the quarter as a turning point, saying Scholar Rock is operating from a position of strength as it transitions into a commercial-stage company. He emphasized that ISEMBYLD is the first and only muscle-targeted therapy approved for SMA and said early launch indicators support the opportunity to serve the estimated 6,600 U.S. patients already on SMN2-targeted therapy. His tone was confident and urgent, stressing broad access, a global rollout, and a long runway for the franchise.
Vikas Sinha highlighted that the company remains in a very strong financial position while investing with discipline. He cited $0.6 million in third-quarter revenue, $106.6 million in operating expenses, $17.9 million of noncash stock-based compensation, and $413.6 million of quarter-end cash, cash equivalents and marketable securities. He also pointed to the pending $205 million priority review voucher sale and the additional $150 million available under the debt facility as sources of nondilutive funding for launch, global expansion, supply chain, and pipeline work.
Analysts focused on early launch friction, especially payer access, the 60 to 90 day path from prescription to infusion, and whether the bone fracture warning was affecting demand; management said the warning has had no impact and that the main delays are typical launch dynamics such as prior authorization, payer policy buildout, and formulary timing. Management also said Anthem and Centene have published policies aligned with the label, that additional label-aligned policies should come over the next 6 months, and that payer approvals so far have not been limited by age, geography, or site of care. On the pipeline side, management said a subcutaneous apitegromab path could be supported by PK/PD bridging but that the final regulatory path still needs to be discussed with FDA and other regulators.
The call showed an unusually strong start to a first-in-class rare-disease launch: broad patient interest, rapid field execution, and early payer policy wins. Management also has multiple growth drivers beyond the U.S. launch, including Europe, Japan, the subcutaneous apitegromab program, OPAL in younger SMA patients, and FORGE in FSHD.
Near-term revenue is likely to remain small because management expects most patients enrolled through October to start infusions in 2027, not in 2026. Access is still the main bottleneck, with initial denials, prior authorizations, unspecified J-code use until April 1, 2027, and hospital formulary processes all delaying time to infusion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.7%
- Shares Outstanding
- 122.00M
- Float Shares
- 100.94M
of shares held by institutions
317 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 18.21M | ▲ 212.09K |
| Blackrock, Inc. | 9.56M | ▲ 64.44K |
| Siren, L.L.C. | 9.38M | ▼ 200.00K |
| Samsara Biocapital, LLC | 6.90M | 0 |
| Price T Rowe Associates Inc | 6.79M | ▲ 588.22K |
| Wellington Management Group Llp | 6.73M | ▲ 9.43K |
| Orbis Allan Gray Ltd | 5.93M | ▲ 1.75M |
| Vanguard Group Inc | 5.20M | ▲ 280.54K |
| Vanguard Capital Management LLC | 4.81M | ▲ 37.38K |
| Massachusetts Financial Services Co | 4.66M | ▲ 2.05M |
| State Street Corp | 4.38M | ▼ 353.27K |
| Redmile Group, LLC | 4.31M | ▼ 4.76M |
Held by 394 ETFs
Biggest fund positions in SRRK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 26, 26 | AKKARAJU SRINIVAS | buy | 48,988 |
| Oct 23, 26 | AKKARAJU SRINIVAS | buy | 500 |
| Oct 23, 26 | AKKARAJU SRINIVAS | buy | 47,000 |
| Oct 26, 26 | AKKARAJU SRINIVAS | buy | 97,982 |
| Oct 23, 26 | AKKARAJU SRINIVAS | buy | 1,000 |
| Oct 23, 26 | AKKARAJU SRINIVAS | buy | 94,000 |
| Sep 24, 26 | Woods Keith | other | 48,034 |
| Sep 21, 26 | Hallal David | other | 36,652 |
| Jul 1, 26 | FLIER JEFFREY S. | sell | 1,568 |
| Jul 1, 26 | FLIER JEFFREY S. | sell | 1,470 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SRRK coverage
Recent articles, reports, and earnings notes.
No research on SRRK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRRK report →Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 13
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 10
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
businesswire.com · Nov 10
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
gurufocus.com · Oct 20
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.